Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer

Authors: Guo-Liang Yang, Lian-Hua Zhang, Juan-Jie Bo, Hai-Ge Chen, Ming Cao, Dong-Ming Liu, Yi-Ran Huang

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is a novel anti-apoptotic gene, and overexpression of UHRF1 is involved in tumorigenicity. Here, immunohistochemistry was used to detect UHRF1 expression in non-muscle-invasive bladder cancer (NMIBC), and these data were examined for correlation with clinicopathological parameters and prognosis. The UHRF1 expression rate was 49.2% in a total of 118 bladder cancer tissues, which was significantly higher than in normal tissues, and UHRF1 expression has a significantly positive correlation with tumor grade (P = 0.027) and recurrence (P = 0.013). Survival analysis showed that UHRF1 high expression patients’ mean survival time (42.59 months) was significantly shorter than that (71.36 months) of UHRF1 low expression patients (P = 0.0002). Multivariate analysis showed that UHRF1 overexpression was an independent prognostic factor for tumor recurrence (P < 0.0001). So UHRF1 may be a molecular marker to predict the recurrence of NMIBC.
Literature
1.
3.
go back to reference Reuter VE. Bladder. risk and prognostic factors—a pathologist’s perspective. Urol Clin North Am. 1999;26(3):481–92.PubMedCrossRef Reuter VE. Bladder. risk and prognostic factors—a pathologist’s perspective. Urol Clin North Am. 1999;26(3):481–92.PubMedCrossRef
4.
go back to reference Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163(1):73–8.PubMedCrossRef Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163(1):73–8.PubMedCrossRef
5.
go back to reference Muto M, Utsuyama M, Horiguchi T, et al. The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines. Cell Prolif. 1995;28(12):645–57.PubMedCrossRef Muto M, Utsuyama M, Horiguchi T, et al. The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines. Cell Prolif. 1995;28(12):645–57.PubMedCrossRef
6.
go back to reference Fujimori A, Matsuda Y, Takemoto Y, et al. Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation. Mamm Genome. 1998;9(12):1032–5.PubMedCrossRef Fujimori A, Matsuda Y, Takemoto Y, et al. Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation. Mamm Genome. 1998;9(12):1032–5.PubMedCrossRef
7.
go back to reference Uemura T, Kubo E, Kanari Y, et al. Temporal and spatial localization of novel nuclear protein NP95 in mitotic and meiotic cells. Cell Struct Funct. 2000;25(3):149–59.PubMedCrossRef Uemura T, Kubo E, Kanari Y, et al. Temporal and spatial localization of novel nuclear protein NP95 in mitotic and meiotic cells. Cell Struct Funct. 2000;25(3):149–59.PubMedCrossRef
8.
go back to reference Arima Y, Hirota T, Bronner C, et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells. 2004;9(2):131–42.PubMedCrossRef Arima Y, Hirota T, Bronner C, et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells. 2004;9(2):131–42.PubMedCrossRef
9.
go back to reference Bonapace IM, Latella L, Papait R, et al. Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry. J Cell Biol. 2002;157(6):909–14.PubMedCrossRef Bonapace IM, Latella L, Papait R, et al. Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry. J Cell Biol. 2002;157(6):909–14.PubMedCrossRef
10.
go back to reference Papait R, Pistore C, Negri D, et al. Np95 is implicated in pericentromeric heterochromatin replication and in major satellite silencing. Mol Biol Cell. 2007;18(3):1098–106.PubMedCrossRef Papait R, Pistore C, Negri D, et al. Np95 is implicated in pericentromeric heterochromatin replication and in major satellite silencing. Mol Biol Cell. 2007;18(3):1098–106.PubMedCrossRef
11.
go back to reference Bostick M, Kim JK, Esteve PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317(5845):1760–4.PubMedCrossRef Bostick M, Kim JK, Esteve PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317(5845):1760–4.PubMedCrossRef
12.
go back to reference Sharif J, Muto M, Takebayashi S, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007;450(7171):908–12.PubMedCrossRef Sharif J, Muto M, Takebayashi S, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007;450(7171):908–12.PubMedCrossRef
13.
go back to reference Arita K, Ariyoshi M, Tochio H, et al. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature. 2008;455(7214):818–21.PubMedCrossRef Arita K, Ariyoshi M, Tochio H, et al. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature. 2008;455(7214):818–21.PubMedCrossRef
14.
go back to reference Avvakumov GV, Walker JR, Xue S, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455(7214):822–5.PubMedCrossRef Avvakumov GV, Walker JR, Xue S, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455(7214):822–5.PubMedCrossRef
15.
go back to reference Qian C, Li S, Jakoncic J, et al. Structure and hemimethylated CpG binding of the SRA domain from human UHRF1. J Biol Chem. 2008;283(50):34490–4.PubMedCrossRef Qian C, Li S, Jakoncic J, et al. Structure and hemimethylated CpG binding of the SRA domain from human UHRF1. J Biol Chem. 2008;283(50):34490–4.PubMedCrossRef
16.
go back to reference Achour M, Jacq X, Ronde P, et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. 2008;27(15):2187–97.PubMedCrossRef Achour M, Jacq X, Ronde P, et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. 2008;27(15):2187–97.PubMedCrossRef
17.
go back to reference Jeanblanc M, Mousli M, Hopfner R, et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene. 2005;24(49):7337–45.PubMedCrossRef Jeanblanc M, Mousli M, Hopfner R, et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene. 2005;24(49):7337–45.PubMedCrossRef
18.
go back to reference Hopfner R, Mousli M, Jeltsch JM, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase II alpha expression. Cancer Res. 2000;60(1):121–8.PubMed Hopfner R, Mousli M, Jeltsch JM, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase II alpha expression. Cancer Res. 2000;60(1):121–8.PubMed
19.
go back to reference Mousli M, Hopfner R, Abbady AQ, et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 2003;89(1):120–7.PubMedCrossRef Mousli M, Hopfner R, Abbady AQ, et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 2003;89(1):120–7.PubMedCrossRef
20.
go back to reference Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F–1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23(46):7601–10.PubMedCrossRef Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F–1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23(46):7601–10.PubMedCrossRef
21.
go back to reference Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 2005;129(5):1454–63.PubMedCrossRef Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 2005;129(5):1454–63.PubMedCrossRef
22.
go back to reference Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol. 2005;36(10):1101–7.PubMedCrossRef Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol. 2005;36(10):1101–7.PubMedCrossRef
23.
go back to reference Unoki M, Kelly JD, Neal DE, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer. 2009;101(1):98–105.PubMedCrossRef Unoki M, Kelly JD, Neal DE, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer. 2009;101(1):98–105.PubMedCrossRef
24.
go back to reference Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell. 2005;16(12):5621–9.PubMedCrossRef Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell. 2005;16(12):5621–9.PubMedCrossRef
25.
go back to reference Bronner C, Achour M, Arima Y, et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther. 2007;115(3):419–34.PubMedCrossRef Bronner C, Achour M, Arima Y, et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther. 2007;115(3):419–34.PubMedCrossRef
26.
go back to reference Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res. 2000;462(2–3):311–22.PubMed Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res. 2000;462(2–3):311–22.PubMed
27.
go back to reference Abbady AQ, Bronner C, Trotzier MA, et al. ICBP90 expression is downregulated in apoptosis-induced Jurkat cells. Ann N Y Acad Sci. 2003;1010:300–3.PubMedCrossRef Abbady AQ, Bronner C, Trotzier MA, et al. ICBP90 expression is downregulated in apoptosis-induced Jurkat cells. Ann N Y Acad Sci. 2003;1010:300–3.PubMedCrossRef
28.
go back to reference Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 2005;95(3):425–31.PubMedCrossRef Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 2005;95(3):425–31.PubMedCrossRef
29.
go back to reference Dekairelle AF, Tombal B, Cosyns JP, Gala JL. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(13):4724–32.PubMedCrossRef Dekairelle AF, Tombal B, Cosyns JP, Gala JL. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(13):4724–32.PubMedCrossRef
Metadata
Title
UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer
Authors
Guo-Liang Yang
Lian-Hua Zhang
Juan-Jie Bo
Hai-Ge Chen
Ming Cao
Dong-Ming Liu
Yi-Ran Huang
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9983-z

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue